HBV reactivation can cause severe liver injury with jaundice, hepatic failure, and death.
Occurs in patients receiving immunosuppressive drug therapy.
Prophylactic anti viral therapy is highly effective in preventing HBV reactivation.
Rate of HBV reactivation among patients who are HB-sAg-positive and receiving chemotherapy is 40%.
Among patients who have reactivation on chemotherapy, the risk of liver failure is 13% in the risk of mortality is 16%.